Brainstorm considering Right to Try for NurOwn access

Status
Not open for further replies.

jaclyn

New member
Joined
Jun 4, 2018
Messages
8
Reason
Loved one DX
Diagnosis
04/2017
Country
US
State
NY
City
NYC
Thought you guys might be interested to hear how the Brainstorm conference call went today. Seems like the CEO Chaim Lebovits really wants to make NurOwn available but the logistics are up in the air and nothing is confirmed:

https://www.biocentury.com/bc-extra.../brainstorm-considering-right-try-als-therapy

Some key takeaways:

---Lebovits declined to estimate the cost for NurOwn beyond saying that cost of manufacturing and delivering the therapy is similar to CAR T cancer therapies. Yescarta, a CAR T therapy from the Kite Pharma Inc. unit of Gilead Sciences Inc., has a wholesale acquisition cost (WAC) of $373,000

---'On the conference call, he said BrainStorm “won’t go forward [with providing access under right to try] unless we have at least a partial answer to those who cannot afford it.”'

---He also said that if it provides NurOwn under right to try, BrainStorm will charge for the therapy. The law does not restrict companies’ abilities to charge for unapproved therapies.

---He told BioCentury the company could potentially offer NurOwn under right to try to 40 or 50 patients per year.

---BrainStorm is consulting ethicists, patients and clinicians to determine which patients would be given access if the company decides to make it available under right to try, Lebovits told BioCentury.
 
Last edited:

KarenNWendyn

Moderator
Forum Supporter
Joined
Jul 29, 2017
Messages
3,762
Reason
PALS
Diagnosis
07/2017
Country
US
State
OR
City
Southern Oregon
Sounds like “Go fund me” is going to be getting a lot of buisness from the ALS community.
 

KarenNWendyn

Moderator
Forum Supporter
Joined
Jul 29, 2017
Messages
3,762
Reason
PALS
Diagnosis
07/2017
Country
US
State
OR
City
Southern Oregon
Please also refer to the thread on NurOwn in the “Drig Trials” subforum for additional discussion.
 
Status
Not open for further replies.
Top